Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium

Cancer Research

Volumn 68, Issue 20, 2008, Pages 8626-8634

  Benetti, Anna ^a   Berenzi, Angiola ^a   Gambarotti, Marco ^a   Garrafa, Emirena ^a   Gelati, Maurizio ^b   Dessy, Enrico ^a   Portolani, Nazario ^a   Piardi, Tullio ^a   Giulini, Stefano Maria ^a   Caruso, Arnaldo ^a   Invernici, Gloria ^b   Parati, Eugenio Agostino ^b   Nicosia, Roberto ^c   Alessandri, Giulio ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; ENDOGLIN; FIBRONECTIN; HERMES ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ARTICLE; CELL ISOLATION; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; LIVER BIOPSY; LIVER CELL CARCINOMA; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ANTIGENS, CD; ANTIGENS, CD44; CADHERINS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 54249139202     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1218     Document Type: Article

References (50)

1. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19:3-23.
2. El-Serag HB, Davila JA, Petersen NJ, et al. The continue increase in the incidence of hepatocellular carcinoma in United States: an update. Ann Intern Med 2003;139:817-23.
3. Arbuthnot P, Capovilla A, Kew M. Putative role of hepatitis B virus in hepathocarcinogenesis: effect on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 2000;15:357-68.
4. Ozturk M. Genetic aspect of hepatocellular carcinogenesis. Semin Liver Dis 1999;19:235-42.
5. Marotta F, Vangieri B, Cecere A, et al. The pathogenesis of hepathocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ther 2004;155:187-99.
6. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242:151-67.
7. Bruix J, Sherman M, Liovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
9. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advance or metastatic non-small-cell lung cacer. J Clin Oncol 2004;11:2184-91.
11. Ferrara N. VEGF and the quest for tumor angiogenesisfactors. Nat Rev Cancer 2002;2:795-803.
12. Poon RT, Ng IO, Lau C, et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001;233:227-35.
13. Park YN, Kim YB, Yang KM, et al. Incresead expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogeneis. Arch Pathol Lab Med 2000;124:1061-5.
14. Cui S, Hano H, Sakata A, et al. Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol Int 1996;46:751-6.
15. Sakamoto M, Ino Y, Fujii T, et al. Phenotypic changes in tumor vessels associated with the progression of hepatocellular carcinoma. Jpn J Clin Oncol 1993;23:98-104.
16. Nakamura S, Muro H, Suzuki S, et al. Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. Hepatology 1997;26:407-15.
17. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interact with signalling receptor complex of multiple members of the transforming growth factor-h superfamily. J Biol Chem 1999;267:19027-30.
18. Yao Y, Pan Y, Chen J, et al. Endoglin (CD105) expression in angiogenesis of primarly hepatocellular carcinomas: analysis using tissue microarrays and comparison with CD34 and VEGF. Ann Clin Lab Sci 2007;37:39-48.
19. Ho JW, Poon RT, Sun CK, et al. Clinicopathological and prognostic implication of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. Word J Gastroenterol 2005;11:176-81.
20. Yu D, Zhuang L, Sun X, et al. Particular distribution and expression pattern of endoglin (CD105) in liver of patients with hepatocellular carcinoma. BMC Cancer 2007;7:122-31.
21. Tsai JF, Jeng JE, Chuang LY, et al. Clinical evaluation of urinary transforming growth factor β-1 and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Br J Cancer 1997;75:1460-7.
22. Yagmur E, Rizk M, Stanzel S, et al. Elevation of endoglin (CD105) in serum of patients with liver cirrhosis and carcinoma. Eur J Gastroenterol Hepatol 2007;19:755-61.
23. Ali MA, Koura BA, el-Mashad N, et al. The Bcl-2 and TGF-β1 level in patients with chronic hepatitis C, liver cirrhosis and hepatocellular carcinoma. Egypt J Immunol 2004;11:83-90.
24. Warrington K, Hillarbay MC, Li C, Letarte M, Kumar S. Functional role of CD105 in TFGβ1 signaling in murine and human endothelial cells. Anticancer Res 2005;25:1851-64.
25. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenic blood vessels. Oncogene 2003;22:6557-63.
26. Edmonson HA, Stainer PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necroopsies. Cancer 1945;7:462-563.
27. Gasparini G, Harris AR. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-82.
28. Garrafa E, Alessandri G, Benetti A, et al. Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils. J Cell Physiol 2006;207:107-13.
29. Sankar S, Mahooti-Brooks N, Bensen L, et al. Modulation of transforming growth factor β receptor levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 1996;97:1436-46.
30. Alessandri G, Pagano S, Bez A, et al. Isolation and culture of human muscle-derived stem cells able to differentiate into myogenic and neurogenic cell lineages. Lancet 2004;364:1872-83.
31. Alessandri G, Chirivi RGS, Fiorentini S, et al. Phenotypic and functional characterizationof tumor-derived microvascular endothelial cells. Clin Exp Metastasis 1999;17:655-62.
32. Alessandri G, Raju KS, Gullino PM. Interaction of gangliosides with fibronectin in mobilization of capillary endothelium. Invasion Metastasis 1986;6:145-65.
33. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implication for diagnosis and therapy. Clin Cancer Res 1995;1:1623-34.
34. Cao G, Savani RC, Fehrenbach M, et al. Involvement of endothelial CD44 in vivo angiogenesis. Am J Pathol 2006;169:325-36.
35. Damalas A, Ben-Ze'ev A, Simcha I, et al. Excesss of β-catenin promotes accumulation of transcriptionally active P53. EMBO J 1999;18:3054-63.
36. Conacci-Sorrel M, Zhurinski J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signalling and cancer. J Clin Invest 2002;109:987-91.
37. Tettis B, Pineau P, Bregeaud L. Close correlation between β-catenin gene alteration and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18:6583-8.
38. Invernici G, Ponti D, Corsini E, et al. Human microvascular endothelial cells from different fetal organs demonstrate organo-specific CAM expression. Exp Cell Res 2005;308:273-82.
39. Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994;73:2275-9.
40. Washington K, Telen MJ, Gottfried MR. Expression of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study. Liver 1997;17:17-23.
41. Sun B, Zhang S, Zhang D, et al. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006;16:693-8.
42. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessels regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356-62.
43. Seay U, Sedding D, Crick S, Hacker M, Seeger W, Eickelberg O. Transforming Growth Factor-β-dependent growth inibition in primary vacsular smooth muscle cells is P38-dependent. JEPT 2005;315:1005-12.
44. Morikawa S, Baluk P, Kaidoh T, Haskel A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
45. Rossmanith W, Schulte-Hermann R. Biology of transforming growth factor β in hepatocarcinogenesi. Microsc Res Tech 2001;52:430-6.
46. Weller M, Wick W, Platten M. Role of TGFβ in oncogenesis. Microsc Res Tech 2001;52:353-63.
47. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 1998;22:656-62.
48. Mishra L, Shetty K, Tang Y, et al. The role of TGF-β and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005;24:5775-89.
49. Dong Y, Drissi H, Chen M, et al. Wnt-mediated regulation of chondrocyte maturation: modulation by TGF-β. J Cell Biochem 2005;95:1057-68.
50. Breitkopf K, Haas S, Wiercinska E, et al. Anti-TGF-β strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005;29:121-31S.